<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5259">
  <stage>Registered</stage>
  <submitdate>13/08/2015</submitdate>
  <approvaldate>13/08/2015</approvaldate>
  <nctid>NCT02526420</nctid>
  <trial_identification>
    <studytitle>Versartis International Trial in Adults With Long-Acting Growth Hormone</studytitle>
    <scientifictitle>An Open-Label, Dose Finding, International Phase 2 Study With Once Monthly Subcutaneous VRS-317 in Adult Growth Hormone Deficiency (GHD)</scientifictitle>
    <utrn />
    <trialacronym>VITAL</trialacronym>
    <secondaryid>15VR7</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Adult Growth Hormone Deficiency</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other endocrine disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - somavaratan

Experimental: Cohort A: Somavaratan in Older Adults - Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects &gt;= 35 years of age

Experimental: Cohort B: Somavaratan in Younger Adults - Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in subjects &lt; 35 years of age

Experimental: Cohort C: Somavaratan in Women on Estrogen - Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly in female subjects on oral estrogen (regardless of age)


Treatment: drugs: somavaratan
Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Safety as measured by the number of subjects with adverse events, concomitant medications, safety labs, vital signs and physical exams - Safety observations include adverse events, concomitant medications, safety labs, vital signs and physical exams.</outcome>
      <timepoint>5 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Starting doses (proportion of subjects who achieve normalization of IGF-I SDS response during the first dosing interval ) - To evaluate the starting doses of VRS-317 for each cohort as measured by the proportion of subjects who achieve normalization of IGF-I SDS response during the first dosing interval (one month after the first dose)</outcome>
      <timepoint>5 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Dose titration plan (proportion of subjects who achieve a mean IGF-I SDS within the defined target range after each dose titration) - To evaluate the dose titration plan of VRS-317 for each cohort as measured by the proportion of subjects who achieve a mean IGF-I SDS within the defined target range after each dose titration</outcome>
      <timepoint>5 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity of VRS-317 by measurement of serum anti-drug antibody (ADA) titers - To evaluate the immunogenicity of VRS-317 by measurement of serum anti-drug antibody (ADA) titers</outcome>
      <timepoint>5 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Immunogenicity of VRS-317 by detection of neutralizing antibodies (NAbs) - To evaluate the immunogenicity of VRS-317 by detection of neutralizing antibodies (NAb)</outcome>
      <timepoint>5 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Female subjects of childbearing potential must have negative pregnancy test and use
             appropriate contraceptive methods

          -  Subjects must have documented GHD during adulthood.

          -  Subjects taking other hormone replacement therapy must have been on a stable course of
             treatment for at least 3 months.

          -  Subjects with underlying disorders responsible for the subject's GHD must have been
             clinically stable for at least 6 months.

          -  Subjects receiving daily rhGH injections must washout for 14 days.

          -  Subjects must provide signed informed consent.

          -  Subjects must have a BMI (kg/m2) between 19.0 and 35.0.</inclusivecriteria>
    <inclusiveminage>23</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>70</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Subjects with diabetes mellitus or inadequate glucose control

          -  Subjects with untreated adrenal insufficiency.

          -  Subjects with free thyroxine outside the normal reference range.

          -  Subjects currently taking oral glucocorticoids, except for physiological maintenance
             doses of oral glucocorticoids in subjects with multiple pituitary hormone
             deficiencies.

          -  Subjects with current significant cardiovascular disease, heart insufficiency of NYHA
             class &gt; 2.

          -  Subjects with current significant cerebrovascular, pulmonary, neurological, renal,
             inflammatory, or hepatobiliary disease.

          -  Subjects with current papilledema.

          -  Subjects with a history of persistent or recurring migraines.

          -  Subjects with current edema (= CTCAE Grade 2).

          -  Subjects with current drug or alcohol abuse.

          -  Subjects with a documented history of HIV, current HBV or HCV infection

          -  Subjects with a prior history of malignancy excluding adequately treated non-melanoma
             skin cancers or in situ carcinoma of the cervix.

          -  Women who are pregnant or breastfeeding.

          -  Subjects with a significant abnormality in Screening laboratory results</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>36</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD,VIC</recruitmentstate>
    <hospital>Princess Alexandra Hospital - Woolloongabba</hospital>
    <hospital>St Vincent's Hospital - Fitzroy</hospital>
    <hospital>The Alfred Hospital - Melbourne</hospital>
    <postcode>4102 - Woolloongabba</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3004 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Berlin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Essen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>B152gw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Ec1m 6bq</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hu3 2rw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>M20 4bx</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Versartis Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Premier Research Group plc</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A Phase 2, open-label dose-finding safety study of individualized monthly VRS-317 dosing for
      five months in adults with GHD.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02526420</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Daniela Rogoff, MD, PhD</name>
      <address>Versartis Inc.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>